Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)

In by ECIR

Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)

  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

– 18 to 80 years old
– must have a BMI ≥27 and ≤50 kg/m²
– if diabetic A1c <9.5% - diagnosis of NASH with stage 2 or 3 fibrosis by liver biopsy - have had heart attack, stroke, or hospitalization for congestive heart failure in the past 6 months

Exclusion Criteria

– uncontrolled high blood pressure
– eGFR <30 - diagnosis of type 1 diabetes - history of pancreatitis - Liver disease due alcohol, hepatitis B or C, or any other form of liver disease - active cancer within the last 5 years

Back to Current Studies